한글목차

전 세계 헤파린 유도 혈소판 감소증 시장은 2024년에 103억 7,000만 달러에서 2033년에는 164억 8,000만 달러에 달할 것으로 예상되며, 예측 기간인 2025년부터 2033년까지 연평균 5.3%의 CAGR로 성장할 것으로 예상됩니다.

헤파린 유도 혈소판 감소증(HIT)은 혈전 예방 및 치료에 일반적으로 사용되는 항응고제인 헤파린에 노출된 일부 환자에서 발생하는 심각한 면역 매개 부작용으로, 혈소판 수가 현저하게 감소(혈소판 감소)하는 것이 특징이며, 일반적으로 헤파린 노출 후 5-10일 후에 발병합니다. 하지만 이전에 감작된 환자에서는 더 빨리 발병할 수 있습니다.

헤파린 유도 혈소판 감소증(HIT)은 혈전성 합병증의 위험을 줄이기 위해 신속하고 효과적인 치료가 필요합니다. 주요 접근법은 모든 형태의 헤파린을 중단하고 대체 항응고 요법을 시작하는 것입니다.

시장 역학:

촉진요인과 억제요인

헤파린 사용량 증가

HIT의 유병률은 헤파린 투여와 직접적인 상관관계가 있기 때문에 헤파린의 사용 증가는 헤파린 유도 혈소판 감소증(HIT) 시장을 크게 견인할 것으로 예상됩니다. 헤파린은 수술 및 심혈관질환 치료 등 다양한 의료 현장에서 널리 사용되는 항응고제입니다. 혈전색전증 예방 및 치료에 효과적이기 때문에 헤파린에 대한 수요가 증가함에 따라 HIT 발생률도 증가할 것으로 예상됩니다. 이러한 발생률 증가로 인해 효과적인 치료 옵션이 필요하며, HIT 치료 시장이 확대될 것으로 예상됩니다.

또한, HIT에 특화된 새로운 치료제와 항응고제의 연구 개발이 진행되고 있는 것도 시장 성장을 더욱 촉진할 것으로 보입니다. 의료 서비스 제공자들은 HIT의 적시 진단 및 관리를 통해 환자의 예후를 개선하는 데 주력하고 있으며, 헤파린의 사용이 증가함에 따라 이 분야의 효과적인 치료 솔루션에 대한 수요가 증가할 것으로 예상됩니다.

질병에 대한 낮은 인지도

의료진과 환자 모두 이 심각한 질환에 대한 지식이 부족한 경우가 많기 때문에 낮은 인지도가 헤파린 유도 혈소판 감소증(HIT) 시장 성장에 큰 걸림돌로 작용할 것으로 예상됩니다. 또한, HIT의 관리에는 대체 항응고제 및 모니터링 프로토콜에 대한 전문적 지식이 필요하며, 의료진이 충분한 교육을 받지 못한 환경에서는 HIT의 관리가 어려울 수 있습니다. 결과적으로 이러한 제한된 인식은 효과적인 치료에 대한 수요를 감소시키고, HIT 관리를 위한 종합적인 치료 전략의 개발을 방해하여 시장 성장을 제한할 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 헤파린 사용 증가
  • 성장 억제요인
    • 질병에 대한 낮은 인식
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 특허 분석
• 규제 분석
• SWOT 분석
• 미충족 수요

제6장 유형별

• Argatroban
• Lepirudin

제7장 투여 경로별

• 비경구
• 경구

제8장 최종사용자별

• 병원
• 전문 클리닉
• 기타

제9장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제10장 경쟁 구도

• 경쟁 시나리오
• 시장 상황·점유율 분석
• M&A 분석

제11장 기업 개요

• Pfizer Inc.
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적평가 지표(KPI)
    • 과거 및 예측 제품 판매
    • 제품 판매량
  • 재무 개요
    • 회사 매출
    • 지역별 수익 분배
    • 매출 예측
  • 주요 발전
    • 인수합병
    • 주요 제품 개발 활동
    • 규제 당국 승인등
  • SWOT 분석
• Novartis AG
• Eagle Pharmaceuticals, Inc.
• Mitsubishi Chemical Group Corporation
• GLAND PHARMA Ltd.
• Teva Pharmaceutical Industries Ltd.
• Verolax Therapeutics

제12장 부록

영문목차

The global heparin induced thrombocytopenia market reached US$ 10.37 billion in 2024 and is expected to reach US$ 16.48 billion by 2033, growing at a CAGR of 5.3% during the forecast period 2025-2033.

Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse reaction that occurs in some individuals exposed to heparin, an anticoagulant commonly used to prevent and treat blood clots. HIT is characterized by a significant drop in platelet count (thrombocytopenia), typically occurring 5 to 10 days after heparin exposure, although it can happen sooner in patients who have been previously sensitized.

Heparin-induced thrombocytopenia (HIT) requires prompt and effective treatment to mitigate the risk of thrombotic complications. The primary approach involves discontinuing all forms of heparin and initiating alternative anticoagulation therapies.

Market Dynamics: Drivers & Restraints

Increasing usage of heparin

The increasing use of heparin is expected to drive the heparin-induced thrombocytopenia (HIT) market significantly, as the prevalence of HIT is directly correlated with heparin administration. Heparin is a widely used anticoagulant in various medical settings, including surgeries and treatment of cardiovascular diseases. As the demand for heparin rises due to its effectiveness in preventing and treating thromboembolic events, the incidence of HIT is also likely to increase. This growing incidence necessitates effective treatment options, thereby expanding the HIT treatment market.

Additionally, the ongoing research and development of new therapies and anticoagulants specifically targeting HIT will further boost market growth. With healthcare providers focusing on improving patient outcomes through timely diagnosis and management of HIT, the increasing use of heparin will create a robust demand for effective treatment solutions in this segment.

Limited awareness of the disease

Limited awareness is expected to hinder the heparin-induced thrombocytopenia (HIT) market significantly, as both healthcare professionals and patients often lack sufficient knowledge about this serious condition. Furthermore, the complexity of HIT management requires specialized knowledge regarding alternative anticoagulants and monitoring protocols, which can be challenging in settings where healthcare providers are not adequately trained. Consequently, this limited awareness can restrict market growth by reducing the demand for effective treatments and hindering the development of comprehensive care strategies for HIT management.

Segment Analysis

The global heparin induced thrombocytopenia market is segmented based on drugs, route of administration, end-user, and region.

Drugs:

Argatroban is expected to dominate the global heparin induced thrombocytopenia market share

Argatroban is expected to dominate the heparin-induced thrombocytopenia (HIT) market due to its unique properties as a direct thrombin inhibitor and its established efficacy in treating this serious condition. As a non-heparin anticoagulant, argatroban is particularly valuable for patients with HIT, where traditional heparin therapy poses significant risks. Its intravenous administration allows for rapid onset of action, making it suitable for emergency settings, especially in hospitals where timely treatment is crucial.

The market for argatroban is projected to grow significantly, driven by an increasing incidence of HIT and rising awareness among healthcare professionals regarding its benefits. Additionally, argatroban's favorable safety profile and effectiveness in patients with renal dysfunction further enhance its appeal as a preferred treatment option. With ongoing clinical studies and potential new indications being explored, argatroban is well-positioned to capture a substantial share of the HIT treatment market in the coming years, reinforcing its role as a key therapeutic agent in managing this condition effectively.

Geographical Analysis

North America is expected to hold a significant position in the global heparin induced thrombocytopenia market share

North America is expected to dominate the heparin-induced thrombocytopenia (HIT) market due to its advanced healthcare infrastructure, high levels of awareness among healthcare professionals, and a significant patient population at risk for HIT. The region accounted for the largest market driven by the increasing incidence of conditions requiring heparin therapy, such as cardiovascular diseases and surgeries.

North American healthcare providers are well-equipped to accurately diagnose and manage HIT, facilitating timely interventions that improve patient outcomes. Furthermore, ongoing research and development efforts in anticoagulant therapies are concentrated in this region, supported by robust regulatory frameworks and funding initiatives. The presence of key pharmaceutical players also enhances innovation and the availability of effective treatment options. As a result, North America is projected to maintain its leadership position in the HIT market, with continued growth anticipated through increased awareness and improved treatment protocols.

Competitive Landscape

The major global players in the heparin induced thrombocytopenia market include Pfizer Inc., Novartis AG, Eagle Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, GLAND PHARMA Ltd., Teva Pharmaceutical Industries Ltd. and Verolax Therapeutics among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Heparin Induced Thrombocytopenia Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drugs
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing usage of heparin
  • 4.1.2. Restraints
    • 4.1.2.1. Limited awareness of the disease
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Argatroban*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Lepirudin

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Parenteral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Novartis AG
• 11.3. Eagle Pharmaceuticals, Inc.
• 11.4. Mitsubishi Chemical Group Corporation
• 11.5. GLAND PHARMA Ltd.
• 11.6. Teva Pharmaceutical Industries Ltd.
• 11.7. Verolax Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us